Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3910278 | 0.98 | HRH3 (0.52) | HRH3KCNH2CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL20761951 | 0.95 | HRH3 (0.42) | HRH3KCNH2CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL20760736 | 0.89 | HRH3 (0.46) | HRH3KCNH2CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL3218443 | 0.86 | L3MBTL1 (0.41) | HRH3KCNH2LOXL3MBTL1MAPT | |
| SCHEMBL2485662 | 0.84 | L3MBTL1 (0.45) | HRH3KCNH2CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL3903913 | 0.83 | PAOX (0.44) | CA1CA2 | |
| Hydrochloric Acid SCHEMBL11534273 | 0.82 | L3MBTL1 (0.43) | HRH3KCNH2CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL13974361 | 0.81 | HRH3 (0.37) | HRH3KCNH2LOXL3MBTL1MAPT | |
| SCHEMBL3900755 | 0.81 | CXCR4 (0.47) | HRH3SMN1; SMN2LOXCA1CA2 | |
| SCHEMBL30425773 | 0.81 | GNAI3 (0.37) | MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723744-B1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | DOMPE FARM SPA (IT) | 2026-03-18 | — | — | EP | claimed |
| EP-4308114-B1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | DOMPE FARM SPA (IT) | 2026-02-11 | — | — | EP | claimed |
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | claimed |
| US-20090306126-A1 | Indole Derivatives | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| US-20090118336-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | claimed |
| EP-2029578-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-04 | — | — | EP | claimed |
| EP-2029593-A1 | INDOLE DERIVATIVES | AstraZeneca AB (SE) | 2009-03-04 | — | — | EP | claimed |
| EP-2016068-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | AstraZeneca AB (SE) | 2009-01-21 | — | — | EP | claimed |
| WO-2007138277-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | claimed |
| WO-2007135398-A1 | INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | claimed |
| WO-2007129052-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| CN-107922362-A | 1,3, 4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | 株式会社钟根堂 | 2018-04-17 | — | — | CN | disclosed |
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | disclosed |
| US-20090306126-A1 | Indole Derivatives | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090118336-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-2016075-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | AstraZeneca AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007138277-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007135398-A1 | INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007129044-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129052-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | MKI67, CCNI, CDK2 | HRH3 2834/4885KCNH2 2260/4885CYP1A2 379/4885 |
| US-20090306126-A1 | Indole Derivatives | MTOR, IDO1, AKT1S1 | HRH3 1126/4885KCNH2 3199/4885CYP1A2 287/4885 |
| US-20090118336-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MTOR, RICTOR, PIK3R5 | HRH3 2059/4885KCNH2 3172/4885CYP1A2 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.